High Complexity Medical Diagnostic Laboratory, 25-Year New Jersey Lab

$10.0M

Revenue

$1.0M

SDE

6.0x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a high-complexity clinical diagnostic laboratory based in Edison, New Jersey, running 24/7 and processing over 500 specimen tests per day. The menu spans advanced molecular diagnostics, genetic testing, complex liquid biopsies, infectious disease panels, urinalysis, and companion diagnostics, all under full regulatory approvals for both routine and high-complexity testing. With more than 90 employees, a private fleet of vehicles with dedicated drivers, and on-site technologists and phlebotomists, the lab serves thousands of referring centers across the Tri-State area.

The business generates roughly $10M in revenue against $1M in reported cash flow, a 10 percent SDE margin that is on the thin side for a lab of this scale and worth understanding in diligence. Its position as a niche molecular, genetic, and rapid point-of-care provider is genuine, and the ability to accept both in-network and out-of-network payers is both an asset and a risk depending on how much of the profit rides on out-of-network reimbursement.

The founder has run the lab for over two decades and is exiting to retire, offering full training and support. The asking price of $6M against $1M cash flow is a 6x multiple, which is rich for an SMB but includes $750K of inventory and a meaningful equipment and vehicle package. The deal is already under contract, so this reads as a benchmark study more than an actionable opportunity.

Why we like it

Diagnostic lab volume is genuinely durable demand. Physicians order tests regardless of the economy, and a facility touching over 500 specimens per day across infectious disease, molecular, and genetic panels is plugged into essential clinical workflows that do not get cut in a downturn.
The 25-year operating history and full high-complexity regulatory approvals are a real moat. CLIA high-complexity certification, payer contracts, and a referring network of thousands of centers take years to build and are not easily replicated by a new entrant.
Recurring referral flow behaves like an annuity. Referring centers send specimens continuously rather than being re-won on each order, so the revenue base has a route-like quality once the physician relationships are in place.
The sale includes $750K of inventory plus lab equipment and a private vehicle fleet. A buyer inherits an operational, turn-key facility with the hard assets and 90-plus trained staff already in place, lowering build-out risk versus starting cold.

How to improve it

Audit the payer mix immediately and quantify how much profit comes from out-of-network billing. Out-of-network reimbursement is the single biggest swing factor in lab economics, and shifting more volume in-network or protecting existing OON contracts should be the first 90-day priority.
Attack the thin 10 percent margin by benchmarking cost per test against reagent, labor, and courier costs. A $10M lab running only $1M in cash flow likely has room in supply contracts and staffing efficiency that a disciplined operator can recover.
Expand the referring center base using the underused advertising channels the listing itself flags. A structured outbound sales effort to physician groups and clinics can add specimen volume against largely fixed lab overhead, dropping incremental revenue to the bottom line.
Add or expand high-value test lines like companion diagnostics and liquid biopsy where reimbursement is strongest. Shifting mix toward higher-margin molecular work leverages the existing high-complexity certification without proportional cost increases.
Tighten revenue cycle management and denial rates. Labs routinely leak cash through claim denials and slow collections, so a review of billing operations and aged receivables can free up working capital and lift realized revenue per test.
Formalize contracts with the largest referring centers to lock in volume. Converting informal relationships into standing agreements protects the revenue base and materially strengthens the story at your own eventual exit.

Diligence notes

Reconcile the $1M cash flow against payer reimbursement risk. Verify what share of revenue and profit depends on out-of-network billing, which is subject to insurer clawbacks, regulatory scrutiny, and reimbursement cuts that could erase margin overnight.
Confirm all CLIA high-complexity certifications, state licenses, and CAP accreditation are current and transferable. Lab licensing is the entire franchise value here, so any lapse, pending inspection, or transfer restriction is a deal killer.
Concentration analysis on referring centers and payers. Find out how many centers drive the majority of specimens and whether any single payer or referral source represents an outsized share of the $10M in revenue.
Investigate any history of payer audits, recoupments, or compliance issues. Diagnostic labs face heightened fraud and abuse scrutiny, so review Medicare/Medicaid billing practices, prior audits, and any settlements before trusting the earnings.
Validate the $750K inventory figure and the condition and ownership of lab equipment and the vehicle fleet. Confirm assets are owned free and clear, not leased or financed, and assess remaining useful life and near-term replacement capex.

Source

Originally listed on BizBuySell. View original listing →